Stanley Druckenmiller Tricida, Inc. Transaction History

Duquesne Family Office LLC

  • $2.95 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 16, 2020
SELL
$8.56 - $26.93 $5.89 Million - $18.5 Million
-688,344 Closed
0 $0
Q4 2019

Feb 14, 2020
BUY
$29.6 - $43.71 $20.4 Million - $30.1 Million
688,344 New
688,344 $26 Million

Others Institutions Holding TCDA

# of Institutions
4
Shares Held
30K
Call Options Held
124K
Put Options Held
46.5K
View Full List

About Tricida, Inc.

TCDA Quotes by TradingView
  • Ticker TCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,668,900
  • Market Cap $557K
  • Description
  • Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...
More about TCDA
Track Stanley Druckenmiller's Portfolio

Track Stanley Druckenmiller Portfolio

Follow Stanley Druckenmiller (Duquesne Family Office LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Duquesne Family Office LLC, based on Form 13F filings with the SEC.

News

Stay updated on Duquesne Family Office LLC and Stanley Druckenmiller with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email